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Abstract
Background: Combining trastuzumab and chemotherapy is standard in her2/neu overexpressing
advanced breast cancer. It is not established however, whether trastuzumab treatment should
continue after the failure of one earlier combination. In this trial, we report our experience with
continued treatment beyond disease progression.
Methods: Fifty-four patients, median age 46 years, range 25–73 years, were included. We analysed
for time to tumour progression (TTP) for first, second and beyond second line treatment, response
rates and overall survival.
Results: Median time of observation was 24 months, range 7–51. Response rates for first line
treatment were 7.4% complete remission (CR), 35.2% partial remissions (PR), 42.6% stable disease
> 6 months (SD) and 14.8% of patients experienced disease progression despite treatment (PD).
Corresponding numbers for second line were 3.7% CR, 22.2% PR, 42.6% SD and 31.5% PD;
numbers for treatment beyond second line (60 therapies, 33 pts 3rd line, 18 pts 4th line, 6 pts 5th
line, 2 pts 6th line and 1 patient 7th line) were 1.7% CR, 28.3% PR, 28.3% SD and 41.6% PD
respectively. Median TTP was 6 months (m) in the first line setting, and also 6 m for second line
and beyond second line. An asymptomatic drop of left ventricular ejection fraction below 50% was
observed in one patient. No case of symptomatic congestive heart failure was observed.
Conclusion:  The data presented clearly strengthen evidence that patients do profit from
continued trastuzumab treatment. The fact that TTP did not decrease significantly from first line to
beyond second line treatment is especially noteworthy. Still, randomized trials are warranted.
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Background
Breast cancer remains the main cause of cancer morbidity
and mortality in women in most countries all over the
world [1,2]. While localised disease is potentially curable,
even in stage I and II disease, 30 % of patients can be
expected to experience a relapse [3]. Especially at risk for
cancer recurrence are patients of young age, nodal positive
tumours and individuals with aggressive tumour pheno-
types, defined as high or intermediate grade, endocrine
receptor negative and/or her2/neu positive [4,5]. When
metastatic disease develops, appropriate therapeutic strat-
egies are necessary to lengthen the patient's survival while
not further reducing her quality of life.
In her2/neu positive tumours, a combination of chemo-
therapy and trastuzumab has proven to produce superior
response rates and a longer time to progression than
chemotherapy alone [6-10]. Trastuzumab is a mono-
clonal humanized antibody targeting the epidermal
growth factor receptor 2 (her2/neu), resulting in an anti-
tumour activity whose exact mechanism of action is not
yet fully understood. Antibody dependent cytotoxicity
(ADCC) is part of this mechanism, but also the blocking
of post-receptor pathways and the inhibition of homo-
and hetero-dimerization are thought to play a crucial role
[11-13]. A benefit however can only be found in tumours
with her2/neu 3+ over-expression in immunohistochem-
istry or in cells with her2/neu gene amplification, which is
usually analysed by FISH (fluorescence in situ hybridisa-
tion) [14]. Paclitaxel plus trastuzumab was the first com-
bination regimen established [15]. While in vitro studies
were able to demonstrate an additive anti-tumour effect of
this combination, other substances (vinorelbine,
docetaxel, and cisplatin) showed a synergistic effect [16].
In vivo, it was possible to demonstrate, that vinorelbine
plus trastuzumab regimens are not only superior to pacli-
taxel containing regimens in terms of toxicity [17], but
also in terms of response and survival [9,10,16,18]. A
recent study found docetaxel plus trastuzumab highly
superior to docetaxel monotherapy as first line palliative
treatment with little additional toxicity [19].
Today, a first line palliative combination of chemotherapy
and trastuzumab can already be deemed standard. Still, it
is not established whether or not patients do achieve a
benefit from continuing trastuzumab treatment com-
bined with a different chemotherapeutic agent after the
failure of one earlier combination, as the way a resistance
to trastuzumab develops is not yet understood entirely.
Because of limited resources, also pharmacoeconomic
aspects must be taken in account.
At our centre, patients were routinely treated with trastu-
zumab also in the second line and beyond second line set-
ting. Individuals were observed prospectively, and we are
reporting our experiences with trastuzumab treatment
after the failure of at least one earlier trastuzumab con-
taining therapy regimen.
Methods
All data were collected at the Department of Internal Med-
icine I, Division of Oncology at the Medical University of
Vienna, Vienna, Austria. Treatment was performed in
accordance with the ethical regulations of the Medical
University of Vienna.
Patients
Fifty-four consecutive patients were included into to this
trial after progressing on first line trastuzumab based
treatment, and were followed prospectively. Prospective
follow up of the first patient started in May 2002. The ret-
rospective starting point of the study (i.e. the date the first
patient received the first cycle of trastuzumab based 1st
line therapy) was June 2001. All patients were suffering
from histological confirmed her2/neu (HERcepTest+++/
FISH positive) positive advanced breast cancer and were
treated with at least two palliative lines of trastuzumab
containing therapy regimens. For staging evaluations, CT-
scan of the chest and the abdomen, mammography,
echocardiography, and gynaecologic examination were
mandatory at baseline.
Treatment plan and patient evaluation
All treatment was administered in the outpatient setting.
Patients received trastuzumab in a dose of 8 mg/kg body
weight loading dose on the first day of treatment, fol-
lowed by 6 mg/kg body weight every three weeks [20]. Re-
evaluation of patients' tumour status was performed with
CT-scan of the chest and the abdomen with additional
work up if indicated every three cycles of therapy. Echocar-
diography was repeated at irregular intervals, longest
every 6 months. Complete response (CR) was defined as
the disappearance of all measurable lesions for a mini-
mum of eight weeks. Partial response (PR) was defined as
25% or more reduction in sum of products of the greatest
diameters of measurable lesions, no increase of lesion size
and no new lesions. Stable disease (SD) was defined as
less than 25% decrease and less than 25% increase with-
out the appearance of new lesions. Progressive disease
(PD) was defined as greater than 25% increase in tumour
size or the appearance of new lesions.
Statistical analysis
Time to progression (TTP) was defined as the interval
from the first day of application of a new therapy line
until tumour progression. Data was analysed as of August
2005. TTP was estimated using the Kaplan-Meier product-
limit method [21]. To test the difference between TTP
curves, the log-rank test was used. p values less than 0.05
were considered to indicate statistical significance. Toxic-BMC Cancer 2006, 6:63 http://www.biomedcentral.com/1471-2407/6/63
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ity was evaluated according to the WHO criteria and was
recorded per patient as the worst episode that occurred on
a certain therapy. Echocardiography data were recorded,
and development of left ventricular function during treat-
ment was reported.
Results
Patient characteristics
Fifty-four patients (53 female/1 male) suffering from
her2/neu positive metastatic breast cancer were included
in this evaluation. Median age was 46 years, range 25–73
years. Table 1 lists the characteristics of all patients
included. 89.8% had invasive ductal carcinoma and
10.2% were suffering from invasive lobular carcinoma.
Twenty-three patients had positive estrogens receptors
and fifteen also a positive progesterone receptor. Thirty-
one patients were treated with adjuvant chemotherapy,
with nineteen patients receiving anthracyclin based regi-
mens and thirteen taxane containing therapies. Adjuvant
endocrine therapy was administered in 15 patients (14
patients received tamoxifen and one anastrozole). Twelve
patients had metastases at the time of primary diagnosis.
Median time to development of metastases in the other 42
patients was 23 months, range 2 – 210 months. Six
patients had only visceral metastases, ten metastases in
the bones and/or the soft tissue, and the remaining 38
patients had metastases of both risk groups. Median
number of metastatic sites was 3, range 1–7 sites. In 14
individuals, a trastuzumab containing combination was
not the first palliative line of treatment. Those patients
had received one earlier line of palliative therapy with aro-
matase inhibitors without trastuzumab.
Most common combination partners were: vinorelbine (n
= 55), docetaxel (n = 28), capecitabine (n = 28), gemcitab-
ine (n = 25), platinum derivatives (n = 13), others (n =
28).
Response and survival data
All fifty-four patients are evaluable for response and toxic-
ity. Median time of observation (all trastuzumab contain-
ing treatment lines) was 24 months, range 7 – 51 months.
Median time of observation in the first line setting was 6
months (range 1 – 17 months), and corresponding num-
bers were median 6 months (range 1 – 24 months) for sec-
ond line, 5 months (range 1 – 41 months) for third line,
Time to progression (months) for 1st, 2nd, 3rd, and 4th line  trastuzumab based combination therapy Figure 1
Time to progression (months) for 1st, 2nd, 3rd, and 4th line 
trastuzumab based combination therapy.
Table 1: Patient characteristics
Characteristics Patients
Entered n = 54
Age median (years) (range) 46 years (range 25 – 73 y)
Estrogen receptor/progesterone 
receptor positive
23/15
HERcepTest+++/FISH+ 51/3
primary metastatic disease 12 (22.2%)
Metastatic sites median (range) 3 (range 1–7 sites)
Lung 22
Liver 29
Bones 30
Lymph nodes 22
Soft tissue 36
Skin 11
Brain 11
Others 3
More than one metastatic site 48 (88.8%)
Adjuvant chemotherapy 31 (57.4%)
Adjuvant docetaxel 13
Adjuvant anthracyclines 19
Adjuvant endocrine therapy 15 (27.7%)
Palliative endocrine therapy 20 (37%)
1st line combination n = 54 pts
Vinorelbine 35
Capecitabine 2
Gemcitabine 0
Docetaxel 12
Platinum derivatives 0
Others 5
2nd line combination n = 54 pts
Vinorelbine 15
Capecitabine 11
Gemcitabine 9
Docetaxel 11
Platinum derivatives 0
Others 8
Beyond 2nd line combination n = 60 therapies
Vinorelbine 6
Capecitabine 14
Gemcitabine 14
Docetaxel 4
Platinum derivatives 11
Others 11BMC Cancer 2006, 6:63 http://www.biomedcentral.com/1471-2407/6/63
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5.5 months (range 3 – 10 months) for fourth line, 4.5
months (range 1 – 12) for fifth line, 7 months (range 6 –
8 months) for sixth line, and 3 months for seventh line
respectively. Response rates for first line combination
treatment were 7.4% complete remission (CR), 35.2%
partial remissions (PR), 42.6% stable disease (SD) and
14.8% of patients experienced disease progression despite
treatment (PD). Corresponding numbers for second line
were 3.7% CR, 22.2% PR, 42.6% SD and 31.5% PD; num-
bers for treatment beyond second line (60 therapies, 33
pts 3rd line, 18 pts 4th line, 6 pts 5th line, 2 pts 6th line and
1 patient 7th line) were 1.7% CR, 28.3% PR, 28.3% SD
and 41.4% PD respectively. Two patients showed
response to a sixth line treatment. Forty-six patients
(85.2%) experienced a clinical benefit (CR + PR + SD≥6
months) from first line treatment, 68.5% from second
line, and 35/60 treatments (58.3%) beyond second line.
TTP was 6 months (m) (range 1–17 m, 95% CI 5.40 –
6.60) in the first line setting, 6 m (1–24 m, 95% CI 5.36 –
6.64) in the second line and also 6 m (1–41 m, 95% CI
5.32 – 6.68) beyond second line. Log rank test revealed no
significant difference between the groups. TTP for 3rd line
was 6 m (range 1–41 m, 95% CI 2.79–9.21), and 4th line
6 m (range 2–10+ m, 95% CI 5.34–6.66) respectively (Fig-
ure 1). TTP for 5th line treatment was 6 months (range 2–
12 m, 95% CI 2.74–9.26) and actual progression time was
median 6 m. No Kaplan-Maier estimations are available
for 6th and 7th line treatment, as only one patient has yet
progressed on 6th line therapy (after 8 months), and the
only patient receiving a 7th line treatment progressed after
3 months. Median survival was not reached after 24
months. Two patients, who experienced disease progres-
sion on first line treatment, responded with PR to second
line therapy. Of three patients with PD in second line
(from a total of sixteen), one showed a PR and four SD
during later lines of therapy. Two patients were lost to fol-
low up at the time of analysis and were therefore not eval-
uable for overall survival.
Toxicity
All side effects are shown in Table 2. Trastuzumab based
therapy was well tolerated and we observed no case of
treatment related death. There was also no case of symp-
tomatic congestive heart failure. In one patient, left ven-
tricular ejection fraction dropped below 50% without
symptoms, therefore necessitating a discontinuation of
therapy. Still, this decrease was fully reversible, and out-
put rate normalised over the next 12 months.
Other toxicities observed were caused by the chemother-
apy agents used as combination partners. A WHO grade IV
neutropenia was observed in 5 patients, with no other
grade IV toxicity reported. WHO grade III toxicities
included stomatitis (2 patients), nausea (1 patient), neu-
tropenia (14 patients), thrombocytopenia (2 patients),
hand-foot-syndrome (3 patients) and anaemia (6
patients).
Discussion
While there is some evidence from different other, mostly
retrospective, trials reporting a benefit from continued
trastuzumab treatment beyond disease progression with a
changed chemotherapy regimen only [22-24], a discon-
tinuation after disease progression is still standard of care.
Though the here presented study is limited by the rela-
tively small number of patients included, we are clearly
able to strengthen existing evidence that there is a benefit
for at least some patients.
The reported decline in response rates from 42.6% in first
line treatment to 30% in beyond second line compares to
the expected drop of response rates with every further line
of chemotherapy or endocrine therapy in palliative treat-
ment. Stable disease and objective response combined,
clinical benefit rates were 85.2% in first line, 68.5% in sec-
ond line and 58.3% in beyond second line. As some other
groups, we believe this to be the more significant parame-
ter in judging the efficacy of palliative treatment, as a sta-
bilisation of the disease without excessive toxicity often
appears more important than objective remission [25,26].
The high clinical benefit rate of nearly 60% even beyond
second line must be seen as a clear sign of a benefit that
most patients gain from treatment continuation. It is also
obvious from our here presented data that this benefit is
Table 2: Toxicities (n = 54 patients). (toxicities shown as worst episode per therapy)
Toxicity WHO grade
I II III IV
Nausea/Vomiting 1 (1.8%) 13 (24.1%) 1 (1.9%) -
Neutropenia - 4 (7.4%) 14 (25.9%) 5 (9.3%)
Thrombocytopenia - 5 (9.3%) 2 (3.7%) -
Anaemia 18 (33.3%) 7 (13%) 6 (11.1%) -
Diarrhoea - 4 (7.4%) - -
Stomatitis - 2 (3.7%) 2 (3.7%) -
Polyneuropathia 1 (1.8%) 2 (3.7%) - -
Hand-Foot-Syndrom 3 (5.6%) 10 (18.1%) 3 (5.6%) -BMC Cancer 2006, 6:63 http://www.biomedcentral.com/1471-2407/6/63
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not paid for by excess toxicity, as apart from a possible
drop in cardiac output rate, no other major toxicity linked
to trastuzumab was observed. This was especially impor-
tant to us, as some patients included in this trial were
treated with trastuzumab for more than 3 years. Notably,
we did not find a case of symptomatic congestive heart
failure. All other toxicities were well within the range
expected from the different chemotherapy regimens. Still,
in one patient, treatment had to be discontinued because
of a drop in ejection fraction below 50%. So while trastu-
zumab based regimens are well tolerated also in medium
and long term treatment, a monitoring of cardiac function
remains essential. Echocardiography only in the case of
symptoms appears not to be sufficient.
Of special interest is the fact, that we did not find a statis-
tical significant difference in TTP between first line, sec-
ond line and beyond second line trastuzumab based
combinations. Although we rather expected to observe a
shortening of time to disease progression with every fur-
ther line of therapy, as this is the usual development in the
metastatic setting, we believe this to be another sign of a
potential benefit from continued combination treatment.
TTP data from the different treatment lines (median 6
months in 1st line, 2nd line and beyond 2nd line) compare
favourably to the data reported in the pivotal trastuzumab
trial with median 6.9 months in combination with pacli-
taxel as first line therapy [27]. As median overall survival
was not yet reached, we believe that our survival data will
be well beyond the median 25.4 months presented in the
pivotal trial. These results are intriguing and somewhat
unexpected, but still the necessity for larger, especially
randomised, trials remains.
A big problem lies in the fact, that the mechanism of
resistance to trastuzumab is not yet fully understood. If
tumour cells are able to switch the main growth pathway
from the her2/neu receptor to the EGFR or other signal
transduction pathways, a continued treatment would not
necessarily lead to a benefit. On the other hand, if no
complete resistance develops, a discontinuation of trastu-
zumab might cause a massive overshoot in tumour
growth, in which case only combination partners should
be switched [28,29]. With limited resources available, also
economic aspects must be taken on account.
Conclusion
In conclusion, we are definitely able to strengthen evi-
dence that her2/neu positive patients do profit from con-
tinued trastuzumab therapy, with a clinical benefit rate of
68.5% in the second line. We are to our best knowledge
the first group reporting a similar TTP in 1st line, 2nd line
and beyond 2nd line treatment, making our data especially
noteworthy. Further, this is among the first studies report-
ing a beneficial role of trastuzumab combination even
beyond second line. Albeit the here presented data, ran-
domised trials are still warranted to make a final conclu-
sion regarding treatment continuation possible.
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